logo-loader
viewTRACON Pharmaceuticals

TRACON earns May 8 date with FDA to discuss pivotal study of its drug envafolimab as a treatment for tissue cancer

In the next six months, TRACON will file an Investigational New Drug for envafolimab in order to conduct the study and apply for orphan drug designation for its use as a treatment for sarcoma

People wearing scrubs and stethoscopes, one points to tablet with a pen
TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates

TRACON Pharmaceuticals Inc (NASDAQ:TCON) has been granted a Type B teleconference meeting with the US Food and Drug Administration on May 8 to discuss a potential pivotal trial of its drug envafolimab as a treatment for the tissue cancer sarcoma.

In a statement, the company said that, during the meeting, it expects to go over the design of the trial, which it has named ENVASARC.

In the next six months, TRACON will file an Investigational New Drug (IND) for envafolimab in order to conduct the study and apply for orphan drug designation for its use as a treatment for sarcoma.

READ: TRACON Pharmaceuticals bolsters its board with appointment of Saundra Pelletier as a director

Additionally, the company will submit a marketing application for envafolimab in China and present clinical data from its corporate partners, 3D Medicine and Alphamab Oncology.

If things go to plan, TRACON will enroll the first patient in ENVASARC within six months.

San Diego-based TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates, as an alternative to expensive contract research organization (CRO) based development.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: TRACON Pharmaceuticals

Price: 2.08 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $11.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners will present positive data from a Phase 2 cancer trial of the drug envafolimab at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. Theuer says the trial enrolled...

1 week, 5 days ago

2 min read